Login Register Cart 0
Generic placeholder image

Current Cardiology Reviews

Editor-in-Chief

ISSN (Print): 1573-403X
ISSN (Online): 1875-6557

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

A Systematic Review of Economic Evidence of Cardiovascular Interventions in India

In Press, (this is not the final "Version of Record"). Available online 30 July, 2024
Author(s): Saba Abidi, Anandita Nair, Rakhi Ahuja, Shridhar Dwivedi and Sushama Talegaonkar*
Published on: 30 July, 2024

Article ID: e300724232473

DOI: 10.2174/011573403X309363240730095253

Price: $95

Abstract

Background: Cardiovascular diseases (CVDs) continue to be the primary cause of mortality globally and invariably in India as well. The rapid upsurge in the prevalence of CVDs in India has created a pressing need to promote contemporary, sustainable, and cost-effective interventions to tackle the CVD burden. This systematic review integrates the research-based evidence of the cost-effectiveness of various interventions that can be adapted to control CVDs in India.

Methods: Databases, namely, PubMed, Cochrane Library, Embase, and Google Scholar, were searched for data on the economic evaluation of interventions targeting CVD based on the Indian population for a period of 30 years (1991-2021). Two reviewers assessed the articles for eligibility, and data were extracted from the shortlisted articles as per a predefined template, including the quantification of methodological aspects.

Results: In total, 1249 studies were examined, out of which 23 completely met the inclusion criteria for full-text review. A total of 16 studies were based solely on the Indian population, while the rest (7) included South Asia/Asia for the intervention, of which India was a participant nation. Most of the economic evaluations targeted treatment-based or pharmacological interventions (14) for CVDs. The evaluations were based on Decision-based models (10), Randomized controlled Trials (RCTs) (9), and Observational studies (4). The cost-effectiveness ratio for the included studies exhibited a diverse range due to variations in methodological approaches, such as differences in study settings, populations, and inconsistencies in study design. The mean ICER (Incremental Cost-effectiveness ratio) for primordial and primary preventions was found to be 3073.8 (US $2022) and 17489.9 (US $2022), respectively. Moreover, the combined mean value for secondary and tertiary prevention was 2029.6 (US$2022).

Conclusion: The economic evidence of public health interventions are expanding, but their focus is restricted towards pharmacological interventions. There is an urgency to emphasize primordial and primary prevention for better outcomes in health economics decision-making. Technology- based avenues for intervention need more exploration in order to cater to a large population like India.

[1]
The changing patterns of cardiovascular diseases and their risk factors in the states of India: The global burden of disease study 1990–2016. Lancet Glob Health 2018; 6: e1339-51.
[http://dx.doi.org/10.1016/S2214-109X(18)30407-8]
[2]
Economic burden of heart disease in India, coronary artery disease in Asian Indians. Available from: https://cadiresearch.org/topic/asian-indian-heart-disease/cadiindia/economic-burden (accessed on 2 February 2021)
[3]
Gupta R, Guptha S, Joshi R, Xavier D. Translating evidence into policy for cardiovascular disease control in India. Health Res Policy Syst 2011; 9(1): 8.
[http://dx.doi.org/10.1186/1478-4505-9-8] [PMID: 21306620]
[4]
Gupta I, Roy A. Economic studies on non-communicable diseases and injuries in India: A systematic review. Appl Health Econ Health Policy 2018; 16(3): 303-15.
[http://dx.doi.org/10.1007/s40258-018-0370-1] [PMID: 29611047]
[5]
Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programs. (2nd ed.), Oxford: Oxford University Press 1997.
[6]
Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ. Cochrane handbook for systematic reviews of interventions version 6.4 (updated August 2023). 2023. Available from: www.training.cochrane.org/handbook
[7]
Abidi S, Labani S, Singh A, Asthana S, Ajmera P. Economic evaluation of human papillomavirus vaccination in the Global South: A systematic review. Int J Public Health 2020; 65(7): 1097-111.
[http://dx.doi.org/10.1007/s00038-020-01431-1] [PMID: 32712694]
[8]
Annual averages in Annual Inflation Rates table, US Inflation Calculator. Available from: https://www.usinflationcalculator.com/inflation/current-inflationrates/ (accessed 15 Nov 2023)
[9]
Singh K, Crossan C, Laba TL, et al. Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial. Int J Cardiol 2018; 262: 71-8.
[http://dx.doi.org/10.1016/j.ijcard.2018.03.082] [PMID: 29622506]
[10]
Shafiq N, Malhotra S, Pandhi P, Sharma N, Bhalla A, Grover A. A randomized controlled clinical trial to evaluate the efficacy, safety, cost-effectiveness and effect on PAI-1 levels of the three low-molecular-weight heparins--enoxaparin, nadroparin and dalteparin. The ESCAPe-END study. Pharmacology 2006; 78(3): 136-43.
[http://dx.doi.org/10.1159/000096484] [PMID: 17057417]
[11]
Lamy A, Tong W, Devereaux PJ, et al. The cost implications of off-pump versus on-pump coronary artery bypass graft surgery at one year. Ann Thorac Surg 2014; 98(5): 1620-5.
[http://dx.doi.org/10.1016/j.athoracsur.2014.06.046] [PMID: 25261272]
[12]
Sanmukhani J, Shah V. Statins. J Postgrad Med 2010; 56(3): 196-200.
[http://dx.doi.org/10.4103/0022-3859.68649] [PMID: 20739765]
[13]
Anchala R, Kaptoge S, Pant H, Di Angelantonio E, Franco OH, Prabhakaran D. Evaluation of effectiveness and cost-effectiveness of a clinical decision support system in managing hypertension in resource constrained primary health care settings: results from a cluster randomized trial. J Am Heart Assoc 2015; 4(1): e001213.
[http://dx.doi.org/10.1161/JAHA.114.001213] [PMID: 25559011]
[14]
Ortegón M, Lim S, Chisholm D, Mendis S. Cost effectiveness of strategies to combat cardiovascular disease, diabetes, and tobacco use in sub-Saharan Africa and South East Asia: mathematical modelling study BMJ 2012; 344(mar02 1): e607.
[http://dx.doi.org/10.1136/bmj.e607] [PMID: 22389337]
[15]
Chisholm D, Sanderson K, Ayuso-Mateos JL, Saxena S. Reducing the global burden of depression. Br J Psychiatry 2004; 184(5): 393-403.
[http://dx.doi.org/10.1192/bjp.184.5.393] [PMID: 15123502]
[16]
Cecchini M, Sassi F, Lauer JA, Lee YY, Guajardo-Barron V, Chisholm D. Tackling of unhealthy diets, physical inactivity, and obesity: health effects and cost-effectiveness. Lancet 2010; 376(9754): 1775-84.
[http://dx.doi.org/10.1016/S0140-6736(10)61514-0] [PMID: 21074255]
[17]
Murray CJL, Lauer JA, Hutubessy RCW, et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: A global and regional analysis on reduction of cardiovascular-disease risk. Lancet 2003; 361(9359): 717-25.
[http://dx.doi.org/10.1016/S0140-6736(03)12655-4] [PMID: 12620735]
[18]
Donaldson EA, Waters HR, Arora M, Varghese B, Dave P, Modi B. A cost-effectiveness analysis of India’s 2008 prohibition of smoking in public places in Gujarat. Int J Environ Res Public Health 2011; 8(5): 1271-86.
[http://dx.doi.org/10.3390/ijerph8051271] [PMID: 21655118]
[19]
Brown HS III, Stigler M, Perry C, Dhavan P, Arora M, Reddy KS. The cost-effectiveness of a school-based smoking prevention program in India. Health Promot Int 2013; 28(2): 178-86.
[http://dx.doi.org/10.1093/heapro/dar095] [PMID: 22271928]
[20]
Basu S, Bendavid E, Sood N. Health and economic implications of national treatment coverage for cardiovascular disease in India. Circ Cardiovasc Qual Outcomes 2015; 8(6): 541-51.
[http://dx.doi.org/10.1161/CIRCOUTCOMES.115.001994] [PMID: 26555122]
[21]
Jha P, Chaloupka FJ, Moore J, et al. Disease control priorities in developing countriesIn: Chapter 46 Tobacco Addiction Washington (DC): The International Bank for Reconstruction and Development / The World Bank New York: Oxford University Press. 2006.
[22]
Schulman-Marcus J, Prabhakaran D, Gaziano TA. Pre-hospital ECG for acute coronary syndrome in urban India: A cost-effectiveness analysis. BMC Cardiovasc Disord 2010; 10(1): 13.
[http://dx.doi.org/10.1186/1471-2261-10-13] [PMID: 20222987]
[23]
Basu S, Yudkin JS, Sussman JB, Millett C, Hayward RA. Alternative strategies to achieve cardiovascular mortality goals in China and India. Circulation 2016; 133(9): 840-8.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.115.019985] [PMID: 26762520]
[24]
Megiddo I, Chatterjee S, Nandi A, Laxminarayan R. Cost-effectiveness of treatment and secondary prevention of acute myocardial infarctiont in India: A modeling study. Glob Heart 2014; 9(4): 391-398.e3.
[http://dx.doi.org/10.1016/j.gheart.2014.07.002] [PMID: 25592792]
[25]
Rodgers A, Lawes CMM, Gaziano TA. Disease control priorities in developing countries.In: Chapter 45 The Growing Burden of Risk from High Blood Pressure, Cholesterol, and Bodyweight 2nd ed Washington (DC): The international bank for reconstruction and development / The World Bank New York: Oxford University Press. 2006.
[26]
Ahuja RC, Mitra MK, Saran RK, Rastogi AC, Goel D. A RCT to estimate cost effectiveness of antihypertensive regimes with or without diuretics for management of mild hypertension. J Clin Epidemiol 1997; 50: S25.
[http://dx.doi.org/10.1016/S0895-4356(97)87242-3]
[27]
Gaziano TA, Reddy KS, Paccaud F. Disease control priorities in developing countries.In: Chapter 33 Cardiovascular Disease 2nd ed Washington (DC): The international bank for reconstruction and development / The World Bank New York: Oxford University Press. 2006.
[28]
Lin JK, Moran AE, Bibbins-Domingo K, et al. Cost-effectiveness of a fixed-dose combination pill for secondary prevention of cardiovascular disease in China, India, Mexico, Nigeria, and South Africa: A modelling study. Lancet Glob Health 2019; 7(10): e1346-58.
[http://dx.doi.org/10.1016/S2214-109X(19)30339-0] [PMID: 31477544]
[29]
Malhotra S, Bhargava VK, Grover A, Pandhi P, Sharma YP. A randomized trial to compare the efficacy, safety, cost and platelet aggregation effects of enoxaparin and unfractionated heparin (the ESCAPEU trial). Int J Clin Pharmacol Ther 2001; 39(3): 110-5.
[http://dx.doi.org/10.5414/CPP39110] [PMID: 11396750]
[30]
Namboodiri KK, Sharma YP, Bali HK, Grover A. Re-use of explanted DDD pacemakers as VDD- clinical utility and cost effectiveness. Indian Pacing Electrophysiol J 2004; 4(1): 3-9.
[PMID: 16943883]
[31]
Nanjappa MC, Dorros G, Hemanna Setty SK, et al. The Indian experience of percutaneous transvenous mitral commissurotomy: Comparison of the triple lumen (inoue) and double lumen (accura) variable sized single balloon with regard to procedural outcome and cost savings. J Interv Cardiol 1998; 11(2): 107-12.
[http://dx.doi.org/10.1111/j.1540-8183.1998.tb00105.x]
[32]
Kamath NA, Patel RS, Sharma KH, Patel N, Thakkar A. Cost-effectiveness analysis of nebivolol and metoprolol in essential hypertension: A pharmacoeconomic comparison of antihypertensive efficacy of beta blockers. Indian J Pharmacol 2014; 46(5): 485-9.
[http://dx.doi.org/10.4103/0253-7613.140577] [PMID: 25298575]
[33]
Sengottuvelu G, Chakravarthy B, Rajendran R, Ravi S. Clinical usefulness and cost effectiveness of fractional flow reserve among Indian patients (FIND study). Catheter Cardiovasc Interv 2016; 88(5): E139-44.
[http://dx.doi.org/10.1002/ccd.25517] [PMID: 24740902]
[34]
Turi ZG, Reyes VP, Raju BS, et al. Percutaneous balloon versus surgical closed commissurotomy for mitral stenosis. A prospective, randomized trial. Circulation 1991; 83(4): 1179-85.
[http://dx.doi.org/10.1161/01.CIR.83.4.1179] [PMID: 2013139]
[35]
Willett WC, Koplan JP, Nugent R. Disease control priorities in developing countries.In: Chapter 44 prevention of chronic disease by means of diet and lifestyle changes 2nd ed Washington (DC): The international bank for reconstruction and development / The World Bank New York: Oxford University Press. 2006.
[36]
Kraus W, Powell K, Haskell WL, et al. Physical activity, all-cause and cardiovascular mortality, and cardiovascular disease. Med Sci Sports Exerc 2019; 51(6): 1270-81.
[http://dx.doi.org/10.1249/MSS.0000000000001939] [PMID: 31095084]
[37]
Reavell J, Hopkinson M, Clarkesmith D, Lane DA. Effectiveness of cognitive behavioral therapy for depression and anxiety in patients with cardiovascular disease: A systematic review and meta-analysis. Psychosom Med 2018; 80(8): 742-53.
[http://dx.doi.org/10.1097/PSY.0000000000000626] [PMID: 30281027]
[38]
Brown A, Barnes C, Byaruhanga J, et al. Effectiveness of technology-enabled knowledge translation strategies in improving the use of research in public health: Systematic review. J Med Internet Res 2020; 22(7): e17274.
[http://dx.doi.org/10.2196/17274] [PMID: 32735231]
[39]
Cortigiani L, Bigi R, Bovenzi F, Molinaro S, Picano E, Sicari R. Prognostic implication of appropriateness criteria for pharmacological pharmacologic stress echocardiography performed in an outpatient clinic. Circ Cardiovasc Imaging 2012; 5(3): 298-305.
[http://dx.doi.org/10.1161/CIRCIMAGING.111.971242] [PMID: 22467675]
[40]
Mansour IN, Lang RM, Aburuwaida WM, Bhave NM, Ward RP. Evaluation of the clinical application of the ACCF/ASE appropriateness criteria for stress echocardiography. J Am Soc Echocardiogr 2010; 23(11): 1199-204.
[http://dx.doi.org/10.1016/j.echo.2010.07.008] [PMID: 20724108]
[41]
Sonaglioni A, Rigamonti E. Appropriate use criteria implementation with modified Haller index for predicting stress echocardiographic results and outcome in a population of patients with suspected coronary artery disease. Int J Cardiovasc Imaging 2021; 37(10): 2917-30.

Rights & Permissions Print Cite
© 2025 Bentham Science Publishers | Privacy Policy